It is therefore the objective of the present invention to provide minigastrin derivates which further improve the accumulation in CCK-2 receptor positive tumours by simultaneously very low accumulation in other organs, e.g. the kidneys. This objective is achieved according to the present invention by a minigastrin derviate having the formula: X-Z-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH 2 (Y), wherein at least one of the connecting or terminal amide bonds between, before or after the amino acids of the sequence Z, Ala, Tyr, Gly, Trp, Met, Asp, Phe and NH 2 or Y (C-terminal) is replaced by a 1,4-disubstituted or a 1,5-disubstituted 1,2,3-triazole, while X stands for a chemical group attached to the peptide for the purpose of diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases, Y stands for C-terminal modifications of the peptide, such as amide, primary and secondary amides, free carboxylic acids and carboxylic ester derivatives including but not limited to amides and esters derived from linear or branched alkyl-,alkenyl-, alkynyl- aromatic-, and heterocyclic alcohols, and Z stands for a linker or DGlu* wherein DGlu* stands for a chain of DGlu having 1 to 6 repetitions (-DGlu- to -DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-). These minigastrin derivates have a high specific internalization, excellent IC 50 values and sufficient plasma stability.La présente invention concerne des dérivés de minigastrine qui améliorent encore l'accumulation dans les tumeurs positives pour le récepteur CCK-2 avec simultanément une très faible accumulation dans d'autres organes, par exemple les reins. La présente invention concerne un dérivé de minigastrine de formule : X-Z-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (Y), dans laquelle au moins l'une des liaisons amide de liaison ou de terminaison entre, avant ou après les acides aminés de la séquence Z, Ala, Tyr, Gly, Trp, Met, Asp, Phe et NH2 ou Y (C-terminal) est remplacé par un groupe 1,2,3-triazole 1,4-disubstitué ou 1,5-disubstitué,
